Cytisinicline

Cytisinicline is now a licensed prescription only medication in the UK.

This short film summarises what cytisinicline offers and urges health and social care organisations to make it available to people who smoke. The film was part-funded by a grant provided by Consilient Health who had no influence or input into the content.

Consilient Health announced the availability of Cytisine from 22nd January 2024 and the NCSCT has written a briefing to help practitioners prepare for supporting their clients to quit using cytisine.

Viatris launched Belnifrem® (cytisinicline) in June 2025 (see summary below).

We will continue to develop resources as we gain more experience and expertise in the use of cytisine. We are also updating our online and virtual training content to support practitioners to prescribe/recommend cytisine.

A recent update from NICE including cytisinicline in their smoking cessation guidelines [NG209] is available here.

In addition to the Cytisinicline Briefing below, we have also included the Cytisine Summary of Product Characteristics (SPC) and an NCSCT Cytisine summary and dosing guide (improved for March 2024).

Our colleagues from Greater Manchester have made an application to their Medicines Management Board to get cytisinicline on their ICB formulary. They have kindly allowed us to post it here as a resource.